Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
TXMD Stock Overview
TherapeuticsMD, Inc. operates as a women’s healthcare company in the United States.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 2 more risks
TherapeuticsMD Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$9.90 |
52 Week High | US$62.50 |
52 Week Low | US$1.99 |
Beta | 2.09 |
1 Month Change | 378.26% |
3 Month Change | -50.56% |
1 Year Change | -83.50% |
3 Year Change | -92.38% |
5 Year Change | -96.24% |
Change since IPO | -80.20% |
Recent News & Updates
TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback
TherapeuticsMD’s $177 million buyout deal with EW Healthcare largely undervalues the biotech. TherapeuticsMD is close to stimulating the commercialization of Annovera which may increase its value as a standalone company in the long run. Shareholders were informed of a 50:1 reverse stock split at the end of Q1 2021 just a few days before the buyout was announced. Investors are in support of the acquisition due to TherapeuticsMD's poor financial position but insist on better terms including an expanded bidding process.
Shareholder Returns
TXMD | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0.2% | 9.1% | 6.6% |
1Y | -83.5% | 12.8% | -18.4% |
Return vs Industry: TXMD underperformed the US Pharmaceuticals industry which returned 12.5% over the past year.
Return vs Market: TXMD underperformed the US Market which returned -18.5% over the past year.
Price Volatility
TXMD volatility | |
---|---|
TXMD Average Weekly Movement | 106.9% |
Pharmaceuticals Industry Average Movement | 11.6% |
Market Average Movement | 8.1% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TXMD is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 48% a day.
Volatility Over Time: TXMD's weekly volatility has increased from 54% to 107% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 416 | Hugh O’Dowd | https://www.therapeuticsmd.com |
TherapeuticsMD, Inc. operates as a women’s healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation.
TherapeuticsMD Fundamentals Summary
TXMD fundamental statistics | |
---|---|
Market Cap | US$87.58m |
Earnings (TTM) | -US$182.05m |
Revenue (TTM) | US$86.42m |
1.0x
P/S Ratio-0.5x
P/E RatioIs TXMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TXMD income statement (TTM) | |
---|---|
Revenue | US$86.42m |
Cost of Revenue | US$19.01m |
Gross Profit | US$67.41m |
Other Expenses | US$249.46m |
Earnings | -US$182.05m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -20.58 |
Gross Margin | 78.00% |
Net Profit Margin | -210.67% |
Debt/Equity Ratio | -144.3% |
How did TXMD perform over the long term?
See historical performance and comparisonValuation
Is TXMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TXMD?
Other financial metrics that can be useful for relative valuation.
What is TXMD's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | US$87.58m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.1x |
Enterprise Value/EBITDA | -2.2x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does TXMD's PS Ratio compare to its peers?
TXMD PS Ratio vs Peers |
---|
Company | PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.8x |
Price-To-Sales vs Peers: TXMD is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (1.8x).
Price to Earnings Ratio vs Industry
How does TXMD's PE Ratio compare vs other companies in the U.S. Pharmaceuticals Industry?
Price-To-Sales vs Industry: TXMD is good value based on its Price-To-Sales Ratio (1x) compared to the US Pharmaceuticals industry average (3.9x)
Price to Sales Ratio vs Fair Ratio
What is TXMD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 1x |
Fair PS Ratio | 717.6x |
Price-To-Sales vs Fair Ratio: TXMD is good value based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (717.6x).
Share Price vs Fair Value
What is the Fair Price of TXMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: TXMD ($9.9) is trading below our estimate of fair value ($81.58)
Significantly Below Fair Value: TXMD is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TXMD's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is TherapeuticsMD forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
1/6Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
61.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TXMD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TXMD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TXMD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TXMD's revenue (20% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: TXMD's revenue (20% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TXMD's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has TherapeuticsMD performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-16.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TXMD is currently unprofitable.
Growing Profit Margin: TXMD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TXMD is unprofitable, and losses have increased over the past 5 years at a rate of 16.3% per year.
Accelerating Growth: Unable to compare TXMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TXMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.7%).
Return on Equity
High ROE: TXMD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
Financial Health
How is TherapeuticsMD's financial position?
Financial Health Score
0/6Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: TXMD has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: TXMD has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: TXMD has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: TXMD's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TXMD has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: TXMD has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15.4% each year
Discover healthy companies
Dividend
What is TherapeuticsMD current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TXMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TXMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TXMD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TXMD's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TXMD has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
6.3yrs
Average management tenure
CEO
Hugh O’Dowd (55 yo)
0.83
Tenure
US$5,567,195
Compensation
Mr. Hugh O’Dowd, M.B.A., serves as President at TherapeuticsMD, Inc. since August 30, 2021 and serves as its Chief Executive Officer since December 14, 2021 and also serves as its Director since December 1...
CEO Compensation Analysis
Compensation vs Market: Hugh's total compensation ($USD5.57M) is above average for companies of similar size in the US market ($USD752.25K).
Compensation vs Earnings: Insufficient data to compare Hugh's compensation with company performance.
Leadership Team
Experienced Management: TXMD's management team is seasoned and experienced (6.3 years average tenure).
Board Members
Experienced Board: TXMD's board of directors are considered experienced (4.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.5%.
Top Shareholders
Company Information
TherapeuticsMD, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: TherapeuticsMD, Inc.
- Ticker: TXMD
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$87.583m
- Shares outstanding: 8.85m
- Website: https://www.therapeuticsmd.com
Number of Employees
Location
- TherapeuticsMD, Inc.
- 951 Yamato Road
- Suite 220
- Boca Raton
- Florida
- 33431
- United States
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/26 00:00 |
End of Day Share Price | 2022/06/24 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.